Jump to content



Recommended Posts

Bristol Myers acknowledged defeat withdrawing Optivo's indication in SCLC that has progressed after platinu-base chemo and at least on other line of therapy.\

The development came 2 years after the failure of 2 confirmatory studies, which were meant to turn Optivo's accelerated approval earned in 2018. 

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.